PO-14 Unsuspected venous thromboembolic disease as a finding of staging procedures in oncology von Cravero, P, Conti, R, Burgos, R, Ochoa, P, Sade, J.P, Martin, C, Petracci, F, Aguirre, M, Giornelli, G, O'Connor, J, Foncuberta, M.C, Zylberman, M, Tartas, N, Chacon, R, Avalos, J. Sanchez

Volltext

LBA7 Nivolumab plus gemcitabine-cisplatin versus gemcitabine-cisplatin alone for previously untreated unresectable or metastatic urothelial carcinoma: Results from the phase III Ch... von van der Heijden, M.S., Sonpavde, G.P., Powles, T.B., Necchi, A., Burotto, M., Schenker, M., Sade, J.P., Bamias, A., Beuzeboc, P., Bedke, J., Oldenburg, J., Urun, Y., Ye, D., He, Z., Perez Valderrama, B., Tomita, Y., Filian, J., Purcea, D., Nasroulah, F., Galsky, M.D.

Volltext

1362MO Pembrolizumab + olaparib vs abiraterone (abi) or enzalutamide (enza) for patients (pts) with previously treated metastatic castration-resistant prostate cancer (mCRPC): Rand... von Yu, E.Y., Park, S.H., Goh, J.C.H., Shin, S.J., Mehra, N., McDermott, R., Sala Gonzalez, M.A., Fong, P.C., Greil, R., Retz, M., Sade, J.P., Huang, Y-H., Begbie, S., Rey, F., Kramer, G., Suzuki, H., Zhang, J., Kim, J., Poehlein, C.H., Antonarakis, E.S.

Volltext

Use of bone health agents (BHAs) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (Ra-223) after abiraterone (Abi): An interim... von Sternberg, C.N., Tombal, B., Miller, K., Saad, F., Sartor, O., Sade, J.P., Logothetis, C., Bellmunt, J., Dizdarevic, S., Harshman, L.C., Logue, J., Baldari, S., Richardson, T., Bottomley, D., Schostak, M., Bayh, I., Kalinovsky, J., Higano, C.

Volltext